Kolon Life Science Statistics
Total Valuation
Kolon Life Science has a market cap or net worth of KRW 221.01 billion. The enterprise value is 320.54 billion.
Market Cap | 221.01B |
Enterprise Value | 320.54B |
Important Dates
The last earnings date was Thursday, November 14, 2024.
Earnings Date | Nov 14, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Kolon Life Science has 12.42 million shares outstanding. The number of shares has increased by 0.46% in one year.
Current Share Class | n/a |
Shares Outstanding | 12.42M |
Shares Change (YoY) | +0.46% |
Shares Change (QoQ) | +0.97% |
Owned by Insiders (%) | 18.06% |
Owned by Institutions (%) | 0.18% |
Float | 6.94M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.45 |
PB Ratio | 1.72 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -3.80 |
EV / Sales | 2.29 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -8.09 |
Financial Position
The company has a current ratio of 0.62, with a Debt / Equity ratio of 0.98.
Current Ratio | 0.62 |
Quick Ratio | 0.33 |
Debt / Equity | 0.98 |
Debt / EBITDA | n/a |
Debt / FCF | -3.16 |
Interest Coverage | -3.38 |
Financial Efficiency
Return on equity (ROE) is -58.21% and return on invested capital (ROIC) is -5.73%.
Return on Equity (ROE) | -58.21% |
Return on Assets (ROA) | -4.33% |
Return on Capital (ROIC) | -5.73% |
Revenue Per Employee | 333.19M |
Profits Per Employee | -200.21M |
Employee Count | 421 |
Asset Turnover | 0.41 |
Inventory Turnover | 2.20 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.21% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -33.21% |
50-Day Moving Average | 18,899.20 |
200-Day Moving Average | 21,670.80 |
Relative Strength Index (RSI) | 39.21 |
Average Volume (20 Days) | 15,248 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kolon Life Science had revenue of KRW 140.27 billion and -84.29 billion in losses. Loss per share was -7,367.96.
Revenue | 140.27B |
Gross Profit | 13.24B |
Operating Income | -23.80B |
Pretax Income | -84.26B |
Net Income | -84.29B |
EBITDA | -15.35B |
EBIT | -23.80B |
Loss Per Share | -7,367.96 |
Balance Sheet
The company has 25.56 billion in cash and 125.10 billion in debt, giving a net cash position of -99.53 billion or -8,011.65 per share.
Cash & Cash Equivalents | 25.56B |
Total Debt | 125.10B |
Net Cash | -99.53B |
Net Cash Per Share | -8,011.65 |
Equity (Book Value) | 127.77B |
Book Value Per Share | 10,361.31 |
Working Capital | -68.85B |
Cash Flow
In the last 12 months, operating cash flow was -29.78 billion and capital expenditures -9.83 billion, giving a free cash flow of -39.60 billion.
Operating Cash Flow | -29.78B |
Capital Expenditures | -9.83B |
Free Cash Flow | -39.60B |
FCF Per Share | -3,187.89 |
Margins
Gross margin is 9.44%, with operating and profit margins of -16.97% and -60.09%.
Gross Margin | 9.44% |
Operating Margin | -16.97% |
Pretax Margin | -60.07% |
Profit Margin | -60.09% |
EBITDA Margin | -10.95% |
EBIT Margin | -16.97% |
FCF Margin | -28.23% |
Dividends & Yields
Kolon Life Science does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.46% |
Shareholder Yield | -0.46% |
Earnings Yield | -41.42% |
FCF Yield | -17.92% |
Stock Splits
The last stock split was on December 27, 2017. It was a forward split with a ratio of 1.5.
Last Split Date | Dec 27, 2017 |
Split Type | Forward |
Split Ratio | 1.5 |
Scores
Kolon Life Science has an Altman Z-Score of -0.07. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -0.07 |
Piotroski F-Score | n/a |